FindTrial
Sign In

Radiomics Study for Prediction of Recurrence in Patients with Primary Hepatic Carcinoma after Interventional therapy

Radiomics Study for Prediction of Recurrence in Patients with Primary Hepatic Carcinoma after Interventional therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019640
Enrollment
Unknown
Registered
2018-11-20
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Case series:Ablation therapy

Sponsors

Beijing Youan Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 2007.1-2015.6 hospitalization and adequate preoperative auxiliary examination (laboratory examination, enhanced CT/MRI examination); 2. pathological diagnosis was HCC; 3. BCLC stage A or B; 4. receive TACE sequential ablation therapy (or without TACE) and the evaluation was complete ablation according to the mRECIST criteria; 5. each patient was followed up until recurrence or the end of 2018.6

Exclusion criteria

Exclusion criteria: 1. The follow-up was less than three years; 2. without the preoperative pathological diagnosis; 3. BCLC stage C or D; 4. the evaluation was incomplete ablation according to the mRECIST criteria; 5. history of intervention therapy; 6. other conditions that do not meet inclusion criteria.

Design outcomes

Primary

MeasureTime frame
recurrence;recurrence free survival;—

Countries

China

Contacts

Public ContactChunwang Yuan

Beijing Youan Hospital Capital Medical University

18612778605@163.com+86 18612778605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026